<VariationArchive RecordType="classified" VariationID="1299297" VariationName="NC000009.12:g.(34646588_34655077)del" VariationType="Deletion" Accession="VCV001299297" Version="1" NumberOfSubmissions="1" NumberOfSubmitters="1" DateLastUpdated="2023-07-29" DateCreated="2021-10-08" MostRecentSubmission="2021-10-08">
  <RecordStatus>current</RecordStatus>
  <Species>Homo sapiens</Species>
  <ClassifiedRecord>
    <SimpleAllele AlleleID="1289157" VariationID="1299297">
      <GeneList>
        <Gene Symbol="GALT" FullName="galactose-1-phosphate uridylyltransferase" GeneID="2592" HGNC_ID="HGNC:4135" Source="submitted" RelationshipType="asserted, but not computed">
          <Location>
            <CytogeneticLocation>9p13.3</CytogeneticLocation>
            <SequenceLocation Assembly="GRCh38" AssemblyAccessionVersion="GCF_000001405.38" AssemblyStatus="current" Chr="9" Accession="NC_000009.12" start="34646675" stop="34651035" display_start="34646675" display_stop="34651035" Strand="+" />
            <SequenceLocation Assembly="GRCh37" AssemblyAccessionVersion="GCF_000001405.25" AssemblyStatus="previous" Chr="9" Accession="NC_000009.11" start="34646585" stop="34650594" display_start="34646585" display_stop="34650594" Strand="+" />
          </Location>
          <OMIM>606999</OMIM>
        </Gene>
      </GeneList>
      <Name>NC000009.12:g.(34646588_34655077)del</Name>
      <VariantType>Deletion</VariantType>
      <FunctionalConsequence Value="complete gene deletion">
        <XRef ID="0169" DB="Variation Ontology" />
      </FunctionalConsequence>
    </SimpleAllele>
    <RCVList>
      <RCVAccession Title="NC000009.12:g.(34646588_34655077)del AND Deficiency of UDPglucose-hexose-1-phosphate uridylyltransferase" Accession="RCV001725923" Version="1">
        <ClassifiedConditionList TraitSetID="949">
          <ClassifiedCondition DB="MedGen" ID="C0268151">Deficiency of UDPglucose-hexose-1-phosphate uridylyltransferase</ClassifiedCondition>
        </ClassifiedConditionList>
        <RCVClassifications>
          <GermlineClassification>
            <ReviewStatus>criteria provided, single submitter</ReviewStatus>
            <Description SubmissionCount="1">Pathogenic</Description>
          </GermlineClassification>
        </RCVClassifications>
      </RCVAccession>
    </RCVList>
    <Classifications>
      <GermlineClassification NumberOfSubmissions="1" NumberOfSubmitters="1" DateCreated="2021-10-08" MostRecentSubmission="2021-10-08">
        <ReviewStatus>criteria provided, single submitter</ReviewStatus>
        <Description>Pathogenic</Description>
        <ConditionList>
          <TraitSet ID="949" Type="Disease" ContributesToAggregateClassification="true">
            <Trait ID="5173" Type="Disease">
              <Name>
                <ElementValue Type="Alternate">GALACTOSEMIA I</ElementValue>
                <XRef Type="Allelic variant" ID="606999.0003" DB="OMIM" />
                <XRef Type="Allelic variant" ID="606999.0006" DB="OMIM" />
                <XRef Type="Allelic variant" ID="606999.0008" DB="OMIM" />
                <XRef Type="Allelic variant" ID="606999.0013" DB="OMIM" />
                <XRef Type="Allelic variant" ID="606999.0001" DB="OMIM" />
                <XRef Type="Allelic variant" ID="606999.0002" DB="OMIM" />
                <XRef Type="Allelic variant" ID="606999.0010" DB="OMIM" />
                <XRef Type="Allelic variant" ID="606999.0015" DB="OMIM" />
                <XRef Type="Allelic variant" ID="606999.0007" DB="OMIM" />
                <XRef Type="Allelic variant" ID="606999.0009" DB="OMIM" />
                <XRef Type="Allelic variant" ID="606999.0014" DB="OMIM" />
                <XRef Type="Allelic variant" ID="606999.0011" DB="OMIM" />
                <XRef Type="Allelic variant" ID="606999.0016" DB="OMIM" />
              </Name>
              <Name>
                <ElementValue Type="Alternate">Galactose-1-phosphate uridyltransferase deficiency</ElementValue>
              </Name>
              <Name>
                <ElementValue Type="Alternate">GALT deficiency</ElementValue>
              </Name>
              <Name>
                <ElementValue Type="Alternate">Galactosemia, classic</ElementValue>
              </Name>
              <Name>
                <ElementValue Type="Alternate">GALACTOSE-1-PHOSPHATE URIDYLYLTRANSFERASE DEFICIENCY</ElementValue>
                <XRef Type="MIM" ID="230400" DB="OMIM" />
              </Name>
              <Name>
                <ElementValue Type="Preferred">Deficiency of UDPglucose-hexose-1-phosphate uridylyltransferase</ElementValue>
                <XRef ID="Deficiency+of+UTP-hexose-1-phosphate+uridylyltransferase/8206" DB="Genetic Alliance" />
                <XRef ID="124354006" DB="SNOMED CT" />
              </Name>
              <Name>
                <ElementValue Type="Alternate">Transferase Deficiency Galactosemia</ElementValue>
              </Name>
              <AttributeSet>
                <Attribute Type="public definition">The term "galactosemia" refers to disorders of galactose metabolism that include classic galactosemia, clinical variant galactosemia, and biochemical variant galactosemia (not covered in this chapter). This GeneReview focuses on: Classic galactosemia, which can result in life-threatening complications including feeding problems, failure to thrive, hepatocellular damage, bleeding, and E coli sepsis in untreated infants. If a lactose-restricted diet is provided during the first ten days of life, the neonatal signs usually quickly resolve and the complications of liver failure, sepsis, and neonatal death are prevented; however, despite adequate treatment from an early age, children with classic galactosemia remain at increased risk for developmental delays, speech problems (termed childhood apraxia of speech and dysarthria), and abnormalities of motor function. Almost all females with classic galactosemia manifest hypergonadatropic hypogonadism or premature ovarian insufficiency (POI). Clinical variant galactosemia, which can result in life-threatening complications including feeding problems, failure to thrive, hepatocellular damage including cirrhosis, and bleeding in untreated infants. This is exemplified by the disease that occurs in African Americans and native Africans in South Africa. Persons with clinical variant galactosemia may be missed with newborn screening as the hypergalactosemia is not as marked as in classic galactosemia and breath testing is normal. If a lactose-restricted diet is provided during the first ten days of life, the severe acute neonatal complications are usually prevented. African Americans with clinical variant galactosemia and adequate early treatment do not appear to be at risk for long-term complications, including POI.</Attribute>
                <XRef ID="NBK1518" DB="GeneReviews" />
              </AttributeSet>
              <Citation Type="review" Abbrev="GeneReviews">
                <ID Source="PubMed">20301691</ID>
                <ID Source="BookShelf">NBK1518</ID>
              </Citation>
              <Citation Type="general" Abbrev="ACMG ACT Sheets, 2010">
                <ID Source="PubMed">21938795</ID>
              </Citation>
              <Citation Type="general" Abbrev="CDC, 2012">
                <ID Source="PubMed">22475884</ID>
              </Citation>
              <Citation Type="review" Abbrev="GeneReviews">
                <ID Source="PubMed">25473725</ID>
                <ID Source="BookShelf">NBK258640</ID>
              </Citation>
              <Citation Type="practice guideline" Abbrev="ACMG Algorithm, 2022">
                <URL>https://www.acmg.net/PDFLibrary/Hypergalactosemia-Algorithm.pdf</URL>
                <CitationText>American College of Medical Genetics Algorithm, Primary or Secondary Hypergalactosemia (Galactose Elevated)</CitationText>
              </Citation>
              <Citation Type="practice guideline" Abbrev="ACMG ACT, 2022">
                <URL>https://www.acmg.net/PDFLibrary/Galactose-ACT-Sheet.pdf</URL>
                <CitationText>American College of Medical Genetics and Genomics, Newborn Screening ACT Sheet, Elevated total galactose with normal GALT enzyme activity, Primary or Secondary Hypergalactosemia, 2022</CitationText>
              </Citation>
              <Citation Type="practice guideline" Abbrev="ACMG ACT, 2021">
                <URL>https://www.acmg.net/PDFLibrary/Classical-Galactosemia-ACT-Sheet.pdf</URL>
                <CitationText>American College of Medical Genetics and Genomics, Newborn Screening ACT Sheet, Absent/Reduced Galactose-1-Phosphate Uridyltransferase (GALT), Classic Galactosemia, 2021</CitationText>
              </Citation>
              <Citation Type="practice guideline" Abbrev="ACMG Algorithm, 2021">
                <URL>https://www.acmg.net/PDFLibrary/GALT-Algorithm.pdf</URL>
                <CitationText>American College of Medical Genetics and Genomics, Algorithm, Galactosemia (GALT Deficiency), 2021</CitationText>
              </Citation>
              <Citation Type="practice guideline" Abbrev="ACMG ACT, 2012">
                <URL>https://www.acmg.net/PDFLibrary/Galactosemia-Transition.pdf</URL>
                <CitationText>American College of Medical Genetics and Genomics, Transition to Adult Health Care ACT Sheet, Galactosemia (GALT Deficiency, Classical Galactosemia), 2012</CitationText>
              </Citation>
              <XRef ID="352" DB="Orphanet" />
              <XRef ID="79239" DB="Orphanet" />
              <XRef ID="C0268151" DB="MedGen" />
              <XRef ID="MONDO:0009258" DB="MONDO" />
              <XRef Type="MIM" ID="230400" DB="OMIM" />
            </Trait>
          </TraitSet>
        </ConditionList>
      </GermlineClassification>
    </Classifications>
    <ClinicalAssertionList>
      <ClinicalAssertion ID="3851952" SubmissionDate="2021-10-04" DateLastUpdated="2021-10-08" DateCreated="2021-10-08">
        <ClinVarSubmissionID localKey="SUB10432728" submittedAssembly="GRCh38" title="SUB10432728" />
        <ClinVarAccession Accession="SCV001950177" DateUpdated="2021-10-08" DateCreated="2021-10-08" Type="SCV" Version="1" SubmitterName="Biochemical Genetics Department, Cyprus Institute of Neurology and Genetics" OrgID="507101" OrganizationCategory="other" />
        <RecordStatus>current</RecordStatus>
        <Classification>
          <ReviewStatus>criteria provided, single submitter</ReviewStatus>
          <GermlineClassification>Pathogenic</GermlineClassification>
          <Comment>This deletion eliminates all GALT exons as well as the non-translated sequences of the adjacent interleukin 11 receptor alpha (IL11RA) gene causing classic galactosemia with additional phenotypic abnormalities such as craniosynostosis (Papachristoforou et al., 2014). Similar deletions of the entire GALT sequence have been also reported in individuals affected with galactosemia (Berry et al., 2001; Bosch et al., 2005; Coffee et al., 2006). Previous reports implicate mutations in the IL11RA gene as being responsible for craniosynostosis (Coussens et al., 2008; Nieminen et al., 2011).The RNA expression studies showed lack of IL11RA transcripts in the patients. These findings strongly suggest that the new deletion simultaneously eliminates GALT and IL11RA expression (contiguous deletion) and for these reasons, this variant meets our criteria to be classified as Pathogenic.</Comment>
        </Classification>
        <Assertion>variation to disease</Assertion>
        <AttributeSet>
          <Attribute Type="ModeOfInheritance">Autosomal recessive inheritance</Attribute>
        </AttributeSet>
        <AttributeSet>
          <Attribute Type="AssertionMethod">ACMG Guidelines, 2015</Attribute>
          <Citation Type="general">
            <ID Source="PubMed">25741868</ID>
          </Citation>
        </AttributeSet>
        <ObservedInList>
          <ObservedIn>
            <Sample>
              <Origin>germline</Origin>
              <Ethnicity>Greek-Cypriot</Ethnicity>
              <GeographicOrigin>Cyprus</GeographicOrigin>
              <Species TaxonomyId="9606">human</Species>
              <Age Type="minimum" age_unit="years">2</Age>
              <Age Type="maximum" age_unit="years">19</Age>
              <AffectedStatus>yes</AffectedStatus>
              <Gender>mixed</Gender>
              <FamilyData NumFamiliesWithVariant="7" />
            </Sample>
            <Method>
              <MethodType>clinical testing</MethodType>
              <MethodAttribute>
                <Attribute Type="StructVarMethodType">Paired-end mapping</Attribute>
              </MethodAttribute>
            </Method>
            <ObservedData>
              <Attribute Type="VariantAlleles" integerValue="6" />
            </ObservedData>
            <ObservedData>
              <Attribute Type="Homozygote" integerValue="3" />
            </ObservedData>
            <ObservedData>
              <Attribute Type="CompoundHeterozygote" integerValue="3" />
            </ObservedData>
            <TraitSet Type="Finding">
              <Trait Type="Finding" ClinicalFeaturesAffectedStatus="present">
                <Name>
                  <ElementValue Type="Preferred">craniosynostosis</ElementValue>
                </Name>
              </Trait>
              <Comment>Patients homozygous for this deletion show additional clinical features such as craniosynostosis, which can be attributed to the defect in the IL11RA gene.</Comment>
            </TraitSet>
          </ObservedIn>
          <ObservedIn>
            <Sample>
              <Origin>germline</Origin>
              <Ethnicity>Greek-Cypriot</Ethnicity>
              <GeographicOrigin>Cyprus</GeographicOrigin>
              <Species TaxonomyId="9606">human</Species>
              <Age Type="minimum" age_unit="years">2</Age>
              <Age Type="maximum" age_unit="years">19</Age>
              <AffectedStatus>no</AffectedStatus>
              <Gender>mixed</Gender>
              <FamilyData NumFamiliesWithVariant="9" />
            </Sample>
            <Method>
              <MethodType>clinical testing</MethodType>
              <MethodAttribute>
                <Attribute Type="StructVarMethodType">Paired-end mapping</Attribute>
              </MethodAttribute>
            </Method>
            <ObservedData>
              <Attribute Type="VariantAlleles" integerValue="9" />
            </ObservedData>
            <ObservedData>
              <Attribute Type="SingleHeterozygote" integerValue="9" />
            </ObservedData>
          </ObservedIn>
        </ObservedInList>
        <SimpleAllele>
          <GeneList>
            <Gene Symbol="GALT">
              <Name>galactose-1-phosphate uridylyltransferase</Name>
            </Gene>
          </GeneList>
          <VariantType>Variation</VariantType>
          <FunctionalConsequence Value="complete gene deletion">
            <XRef DB="Variation Ontology" ID="0169" URL="http://purl.obolibrary.org/obo/VariO_0169" />
          </FunctionalConsequence>
          <AttributeSet>
            <Attribute Type="HGVS">NC000009.12:g.(34646588_34655077)del</Attribute>
          </AttributeSet>
        </SimpleAllele>
        <TraitSet Type="Disease">
          <Trait Type="Disease">
            <XRef DB="OMIM" ID="230400" />
          </Trait>
        </TraitSet>
        <SubmissionNameList>
          <SubmissionName>SUB10432728</SubmissionName>
        </SubmissionNameList>
      </ClinicalAssertion>
    </ClinicalAssertionList>
    <TraitMappingList>
      <TraitMapping ClinicalAssertionID="3851952" TraitType="Disease" MappingType="XRef" MappingValue="230400" MappingRef="OMIM">
        <MedGen CUI="C0268151" Name="Deficiency of UDPglucose-hexose-1-phosphate uridylyltransferase" />
      </TraitMapping>
      <TraitMapping ClinicalAssertionID="3851952" TraitType="Finding" MappingType="Name" MappingValue="craniosynostosis" MappingRef="Preferred">
        <MedGen CUI="C0010278" Name="Craniosynostosis syndrome" />
      </TraitMapping>
    </TraitMappingList>
  </ClassifiedRecord>
</VariationArchive>

